Coherus Promises ‘Compelling Value Proposition’ After US Adalimumab Approval
Yusimry Biosimilar To Humira Set For 1 July 2023 Launch, After Multiple Rivals
As the likely dynamics for US biosimilar competition to Humira come into sharper focus, Coherus has promised that its mid-2023 market entry with its just-approved Yusimry version will be accompanied by a “compelling value proposition,” months after rival Amgen’s biosimilar is expected to launch and around the same time as multiple other rivals are expected to hit the market.
You may also be interested in...
Cigna has responded to several questions from the insurer/payer side on the potential effect of multiple biosimilar Humira products launching in 2023 and beyond.
At an eventful time for US biosimilars, a fresh wave of players entering the market is expected to both increase competition and broaden access, AmerisourceBergen’s senior vice president for global emerging therapies and channel strategy Beth McMahon tells Generics Bulletin.
Coherus BioSciences, juggling both biosimilar and novel biologic assets, has called time on its partnership with China’s Innovent Biologics for biosimilar Avastin – a year after shelving development of biosimilar Eylea.